Get the Stockscreener App
215.70
0.56%
1.20
After Hours:
216.00
0.30
+0.14%
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $215.70, with a volume of 5.38M.
It is up +0.56% in the last 24 hours and up +7.58% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
See More
Previous Close:
$214.50
Open:
$217
24h Volume:
5.38M
Relative Volume:
0.81
Market Cap:
$381.10B
Revenue:
$62.82B
Net Income/Loss:
$3.60B
P/E Ratio:
106.39
EPS:
2.0274
Net Cash Flow:
$19.98B
1W Performance:
+2.52%
1M Performance:
+7.58%
6M Performance:
-8.71%
1Y Performance:
+18.17%
1-Day Range:
$215.70
$220.01
1-Week Range:
$207.68
$220.01
52-Week Range:
$181.72
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, MRK, AZN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
215.70 | 378.98B | 62.82B | 3.60B | 19.98B | 2.0274 |
LLY
Lilly Eli Co
|
1,065.00 | 928.88B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
234.34 | 557.82B | 96.36B | 21.04B | 17.80B | 8.6488 |
MRK
Merck Co Inc
|
122.41 | 286.20B | 65.51B | 8.93B | 14.12B | 3.5532 |
AZN
Astrazeneca Plc
|
187.03 | 294.27B | 60.48B | 10.40B | 8.05B | 3.3297 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Buy |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-08-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-10-25 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-04-25 | Downgrade | DZ Bank | Buy → Hold |
| Oct-14-25 | Downgrade | Erste Group | Buy → Hold |
| Oct-01-25 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Aug-12-25 | Resumed | Piper Sandler | Overweight |
| Aug-07-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
Final trades: AbbVie, Millrose Properties, Archer-Daniels-Midland, GE Vernova and Estee Lauder - MSN
Final Trades: AbbVie, Millrose Properties, Archer-Daniels-Midland, GE Vernova and Estee Lauder - CNBC
Merck (MRK) and AbbVie (ABBV) Gain EU Panel Endorsements for New Treatments - GuruFocus
AbbVie, Merck, Astra among winners of EU drug recommendations this week - Seeking Alpha
AbbVie (ABBV) Receives Positive EMA Opinion for Maviret Approval - GuruFocus
AbbVie Announces Positive CHMP Opinion for MAVIRET® for the Treatment of Acute Hepatitis C Infection - Investing News Network
AbbVie, Novartis slash US headcount - PharmaLive
AbbVie receives EU panel backing for Maviret in acute hepatitis C - Investing.com Canada
AbbVie to present oncology pipeline data at 2026 ASCO meeting - StreetInsider
Opinion: AbbVie Is the Best Dividend King to Buy in an Increasingly Uncertain Market - The Globe and Mail
AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline - Investing News Network
AbbVie stock (US00287Y1091): focus on Humira successors after latest quarterly update - AD HOC NEWS
Allergan Aesthetics Receives Positive CHMP Opinion for Boey® for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults - Investing News Network
艾伯維公司宣佈在2026年美國臨床腫瘤學會（ASCO）年會上公佈新數據，展示其下一代腫瘤學研發管線的廣度與強勁勢頭。 - Moomoo
AbbVie (ABBV) Receives Positive EMA Opinion for Boey Approval - GuruFocus
AbbVie Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Allergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults - Yahoo Finance
Opinion: This program was meant to increase healthcare affordability. The data tell another story. - Crain's Chicago Business
Precision Trading with Abbvie Inc. (ABBV) Risk Zones - Stock Traders Daily
AbbVie Inc. (ABBV) Positioned for Long-Term Gains with IBD Pipeline Strength - Yahoo Finance
AbbVie Inc stock (US00287Y1091): new data, dividend strength and oncology focus draw investor attent - AD HOC NEWS
AbbVie stock (US00287Y1091): focus on immunology pipeline after latest data update - AD HOC NEWS
Three Dividend-Paying Healthcare Giants: Pfizer (PFE), AbbVie (ABBV), and Medtronic (MDT) Compared for 2026 - Blockonomi
High Yield Healthcare Stocks: Why Pfizer, AbbVie, and Medtronic Are Worth Watching in 2026 - CoinCentral
AbbVie stock (US00287Y1091): investors eye Skyrizi and Rinvoq momentum after latest quarterly update - AD HOC NEWS
Ichnos Glenmark Innovation (IGI) Announces New Development Candidate, ISB 2301, a First-in-Class Multispecific Immune Cells Activator Targeting Solid Tumors - GlobeNewswire Inc.
Here is what to know beyond why AbbVie Inc. (ABBV) is a trending stock - MSN
AbbVie stock (US00287Y1091): Q1 2026 earnings beat and Skyrizi, Rinvoq drive fresh momentum - AD HOC NEWS
AbbVie Inc. stock outperforms competitors on strong trading day - MarketWatch
UCB (UCBJY) Reports Bimzelx Success Over AbbVie's Skyrizi in Pso - GuruFocus
Top 12 Undervalued Dividend Stocks to Buy Now - Insider Monkey
UCB says Bimzelx beat AbbVie’s Skyrizi in psoriatic arthritis trial - Seeking Alpha
AbbVie (ABBV) Price Target Lowered to $235 at Evercore ISI - Insider Monkey
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock - Yahoo Finance
2 Reasons to Like ABBV and 1 to Stay Skeptical - Yahoo Finance
Neurotoxin Will Generate Booming Growth Opportunities to 2028 | AbbVie, Ipsen Group, Hugel, Inc., Medytox, Inc. etc. - openPR.com
AbbVie stock (US00287Y1091): Q1 2026 earnings highlight Skyrizi and Rinvoq as growth engines - AD HOC NEWS
AbbVie Inc stock (US00287Y1091): new oncology data and pipeline updates keep focus on long-term grow - AD HOC NEWS
Ill. Panel Sides With AbbVie In Eye-Stent Injury Suit - Law360
Here's How Neuroscience Drugs Boost AbbVie's Q1 Sales Growth - TradingView
TD Private Client Wealth LLC Sells 9,822 Shares of AbbVie Inc. $ABBV - MarketBeat
Mission Wealth Management LP Lowers Holdings in AbbVie Inc. $ABBV - MarketBeat
60,762 Shares in AbbVie Inc. $ABBV Acquired by North Dakota State Investment Board - MarketBeat
AbbVie Inc. $ABBV Shares Purchased by RiverFront Investment Group LLC - MarketBeat
AbbVie Inc. (ABBV) Stock Analysis: Unveiling a 20% Potential Upside Amid Strong Buy Ratings - DirectorsTalk Interviews
AbbVie stock (US00287Y1091): focus on Humira erosion and Skyrizi growth after latest quarterly repor - AD HOC NEWS
AbbVie Inc stock (US00287Y1091): arthritis drug data and dividend keep the spotlight on the pharma g - AD HOC NEWS
AbbVie Inc. $ABBV Shares Sold by WealthPlan Investment Management LLC - MarketBeat
Soltis Investment Advisors LLC Acquires 12,096 Shares of AbbVie Inc. $ABBV - MarketBeat
L & S Advisors Inc Has $8.01 Million Stake in AbbVie Inc. $ABBV - MarketBeat
Millennium Capital Advisors LLC Purchases New Shares in AbbVie Inc. $ABBV - MarketBeat
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.64%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):